12/22
11:14 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
12/22
10:01 am
nrsn
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study [Yahoo! Finance]
Medium
Report
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study [Yahoo! Finance]
12/22
09:17 am
nrsn
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Medium
Report
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
12/13
01:10 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by analysts at
Wall
Medium
Report
NeuroSense Therapeutics (NASDAQ:NRSN) was downgraded by analysts at
Wall
12/4
07:30 am
nrsn
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
Medium
Report
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
11/24
11:04 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NASDAQ:NRSN) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.
11/24
09:56 am
nrsn
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Medium
Report
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
11/3
09:15 am
nrsn
NeuroSense to Host Investor Webinar on December 8, 2025
Medium
Report
NeuroSense to Host Investor Webinar on December 8, 2025
10/17
05:44 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at Zacks Research to a "hold" rating.
10/15
07:11 am
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at Noble Financial to a "strong-buy" rating.
Medium
Report
NeuroSense Therapeutics (NASDAQ:NRSN) was upgraded by analysts at Noble Financial to a "strong-buy" rating.
10/8
12:30 pm
nrsn
NeuroSense Therapeutics (NASDAQ:NRSN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
NeuroSense Therapeutics (NASDAQ:NRSN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/6
09:37 am
nrsn
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers [Yahoo! Finance]
Medium
Report
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers [Yahoo! Finance]
10/6
09:00 am
nrsn
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
High
Report
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers